Entrada Therapeutics(TRDA)
BOSTON, MABiotechnology
Focus: Entrada Therapeutics is a Boston-based public biotech specializing in delivering biologics to the cytosol, addressing rare diseases across neurology, ophthalmology, and gastroenterology. The company is early-stage with a focused pipeline anchored in Duchenne muscular dystrophy.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
6+1 this month
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Should You Work at Entrada Therapeutics?
AI assessmentEntrada is a scientifically differentiated, financially healthy early-stage biotech best suited for risk-tolerant professionals seeking deep technical engagement and equity upside, but with meaningful binary execution risk.
Why Work Here
- Rapidly growing revenue trajectory ($129M → $211M YoY) signals scale-up phase with profitability reached in FY2025 despite only 6 active job openings.
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Slowing
Jobs decreasing
Pipeline & Clinical Trials
Non-interventional
Mitochondrial Neurogastrointestinal EncephalomyopathyClinical Trials (1)
NCT04245917Natural History Study of MNGIE
N/AHelp build intelligence for Entrada Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.